# ABVC BioPharma, Inc. (ABVC) · Edgar & Edgarette company card

> ABVC BioPharma (ABVC) saw revenue fall 41.9% in FY2025 to $0 million, operating margin -2416% against a -3.8% median for pharmaceutical preparations, equity 52.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1173313 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ABVC) · [JSON](https://www.pops4.com/boards/company/ABVC.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $296,000 |
| Revenue growth, 1 year | -41.9% |
| Revenue growth per year | -4.5% |
| Operating margin | -2416.0% (prior year -923.3%) |
| Net margin | -2830.1% |
| Operating cash flow | −$3M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $681,480 |
| Long-term debt | — |
| Total assets | $21M |
| Total equity | $11M |
| Equity ÷ assets | 52.8% |
| Return on equity | -75.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -13.82 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed earlier statements no longer to be relied on, late quarterly report notice, auditor change in the last 12 months; operating cash flow was negative (-$3.0M in FY2025); operating loss: a margin of -2416.0% in FY2025; revenue is hard to predict: its 80% range is ±86%

## Edgarette's reading

Exposure: revenue $296K (FY2025). Experience: revenue down 41.9% on the year, down 4.5% a year over 4 years; operating margin -2416.0%, down from -923.3%. Soundness: equity 52.8% of assets, return on equity -75.4%. Credibility: four or more audited years, moderate weight, marked down from reasonable: on 2026-03-03 the company said earlier statements should no longer be relied on (8-K Item 4.02), and no 10-K has been filed since. Range: 80% of past cases like this landed between $51K and $671K next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $42K to $806K. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -2416.0% against a -3.8% median; growth -41.9% against 13.7%.

Range logged 2026-09-30, receipt 1509d03261ed130a, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 4.02 Earlier statements no longer to be relied on: 1, latest 2026-03-03 ([filing](https://www.sec.gov/Archives/edgar/data/1173313/000121390026023054/0001213900-26-023054-index.htm))
- Item NT 10-Q Late quarterly report notice: 1, latest 2026-05-15 ([filing](https://www.sec.gov/Archives/edgar/data/1173313/000121390026057917/0001213900-26-057917-index.htm))
- Item 4.01 Auditor change: 1, latest 2026-07-02 ([filing](https://www.sec.gov/Archives/edgar/data/1173313/000121390026074949/0001213900-26-074949-index.htm))

## Recent filings

- 10-Q · filed 2026-11-10 · [filing](https://www.sec.gov/Archives/edgar/data/1173313/000121390026118078/0001213900-26-118078-index.htm)
- 8-K · filed 2026-11-02 · 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1173313/000121390026114729/0001213900-26-114729-index.htm)
- DEF 14A · filed 2026-09-29 · [filing](https://www.sec.gov/Archives/edgar/data/1173313/000121390026104509/0001213900-26-104509-index.htm)
- 8-K · filed 2026-08-27 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1173313/000121390026094152/0001213900-26-094152-index.htm)
- 10-Q · filed 2026-08-12 · [filing](https://www.sec.gov/Archives/edgar/data/1173313/000121390026088348/0001213900-26-088348-index.htm)
- 8-K · filed 2026-08-04 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1173313/000121390026084846/0001213900-26-084846-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001173313.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1173313

## Cite

POPS4, Edgar & Edgarette: ABVC BioPharma, Inc. (ABVC) company card, from the company's own SEC filings, accessed 2026-11-14, https://www.pops4.com/boards/company/ABVC. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.